Ghassan Ghorayeb, MD
Ophthalmology · Clarksburg, WVNPI 1962690958
Payments from drug & device makers
Across 201 payments — averaging $4653.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$384K
- Genentech, Inc.$340K
- Bayer$90K
- Novartis$71K
- AbbVie$24K
- Mylan Technologies Inc.$9K
- plus $17K from 9 others
Across 3 payments — averaging $1018.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
What the payments were for
- Travel & lodging$2,75580%
- Food & beverage$67019%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 93 | $383,600 |
| Genentech, Inc. | 31 | $340,371 |
| Bayer | 11 | $89,699 |
| Novartis | 9 | $71,173 |
| AbbVie | 7 | $24,183 |
| Mylan Technologies Inc. | 32 | $9,160 |
| Mylan Inc. | 4 | $7,810 |
| GSK | 3 | $7,187 |
| Eyepoint US, Inc. | 2 | $1,522 |
| Regeneron Healthcare Solutions, Inc. | 4 | $268 |
| Genentech USA, Inc. | 1 | $124 |
| Immunocore Limited | 1 | $122 |
| Apellis Pharmaceuticals, Inc. | 1 | $85 |
| Mallinckrodt Hospital Products Inc. | 1 | $44 |
| Alcon | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$935,365 in reported general payments places this provider in the 95th percentile of 85 ophthalmology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 82 | $3,429 |
| Bromfenac Sodium | 11 | $1,381 |
| MoxifloxacinMoxifloxacin Hcl | 72 | $785 |
| Ketorolac Tromethamine | 29 | $718 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $311 |
| Cyclopentolate Hcl | 35 | $252 |
| Latanoprost | 14 | $212 |
| Brimonidine Tartrate | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Clarksburg
- Anthony RealiniMorgantown$511K
- Vishal VermaHuntington$159K
- Brian McMillanMorgantown$45K
- Joseph SinclairCharleston$9K
- Brian GriffithCharleston$9K
- Stephen CassisMadison$8K
- Jason LudlowCharleston$8K
- David GeorgeParkersburg$7K
- Lawrence MinardiCharleston$7K
- Taoufik SadatHinton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.